TD Asset Management Inc Buys Shares of 15,400 Mirum Pharmaceuticals, Inc. $MIRM

TD Asset Management Inc acquired a new stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 15,400 shares of the company’s stock, valued at approximately $1,129,000.

A number of other large investors have also bought and sold shares of MIRM. CWM LLC lifted its position in shares of Mirum Pharmaceuticals by 30.8% during the 3rd quarter. CWM LLC now owns 683 shares of the company’s stock valued at $50,000 after buying an additional 161 shares during the last quarter. Legal & General Group Plc lifted its holdings in Mirum Pharmaceuticals by 0.4% during the second quarter. Legal & General Group Plc now owns 43,010 shares of the company’s stock valued at $2,189,000 after purchasing an additional 176 shares during the last quarter. MCF Advisors LLC lifted its holdings in Mirum Pharmaceuticals by 76.4% during the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after purchasing an additional 185 shares during the last quarter. Teacher Retirement System of Texas boosted its position in Mirum Pharmaceuticals by 2.2% during the second quarter. Teacher Retirement System of Texas now owns 9,903 shares of the company’s stock worth $504,000 after purchasing an additional 215 shares during the period. Finally, Jones Financial Companies Lllp increased its stake in shares of Mirum Pharmaceuticals by 34.0% in the third quarter. Jones Financial Companies Lllp now owns 957 shares of the company’s stock worth $70,000 after purchasing an additional 243 shares in the last quarter.

Analysts Set New Price Targets

MIRM has been the subject of several analyst reports. Stifel Nicolaus lifted their price objective on shares of Mirum Pharmaceuticals from $98.00 to $125.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Citizens Jmp cut their price target on Mirum Pharmaceuticals from $140.00 to $132.00 and set a “market outperform” rating for the company in a report on Thursday, February 26th. TD Cowen increased their price objective on Mirum Pharmaceuticals from $115.00 to $117.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. HC Wainwright lifted their target price on Mirum Pharmaceuticals from $102.00 to $130.00 and gave the company a “buy” rating in a report on Monday, January 26th. Finally, Raymond James Financial reissued a “strong-buy” rating and issued a $110.00 price target on shares of Mirum Pharmaceuticals in a report on Thursday, December 11th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Mirum Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $117.00.

Mirum Pharmaceuticals Trading Down 5.6%

Shares of Mirum Pharmaceuticals stock opened at $87.84 on Friday. The company has a debt-to-equity ratio of 0.98, a current ratio of 2.67 and a quick ratio of 2.55. Mirum Pharmaceuticals, Inc. has a 1 year low of $36.88 and a 1 year high of $109.28. The firm has a market cap of $5.30 billion, a PE ratio of -183.00 and a beta of 0.52. The company has a 50 day simple moving average of $94.11 and a two-hundred day simple moving average of $79.75.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Wednesday, February 25th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.13). The firm had revenue of $148.93 million for the quarter, compared to the consensus estimate of $141.78 million. Mirum Pharmaceuticals had a negative return on equity of 8.53% and a negative net margin of 4.48%.The company’s revenue for the quarter was up 49.8% on a year-over-year basis. During the same period last year, the firm earned $1.00 EPS. Analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Insider Buying and Selling at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 9,108 shares of the business’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $103.30, for a total value of $940,856.40. Following the completion of the sale, the chief executive officer directly owned 160,294 shares of the company’s stock, valued at $16,558,370.20. The trade was a 5.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Patrick J. Heron bought 131,425 shares of the company’s stock in a transaction that occurred on Friday, January 23rd. The shares were bought at an average price of $68.48 per share, with a total value of $8,999,984.00. Following the completion of the acquisition, the director directly owned 459,010 shares in the company, valued at $31,433,004.80. This trade represents a 40.12% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders sold 45,136 shares of company stock valued at $4,352,029. 14.36% of the stock is currently owned by corporate insiders.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.